What is CVM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CVM?

P/E (TTM) is n/a and 52-week range is $0.89 to $10.62 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CVM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CVM?

The company profile lists revenue (TTM) near $570K, net income (TTM) near $-3.11B, EPS (TTM) near $-2.68 when available from the market-data feed. Figures are informational and may lag live markets.

Where is CEL-SCI Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Vienna, Virginia, US, 17.5M shares outstanding, ISIN US1508377066 when available from company profile and filing metadata.

CEL-SCI Corp

$CVM

Health Care · Biotechnology

IR Run Scenarios

$1.94

-0.51%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. The company is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).

Website

cel-sci.com/

IPO

1983-12-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)